Article in Cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Marco MatejcicDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0009-0004-9468-0664
Jamie K TeerDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0003-4513-0282
Hannah J HoehnDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0001-7056-9671
Diana B DiazNon-Therapeutic Research Office, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0009-0007-7102-4076
Kritika ShankarGenomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio.ORCID 0009-0007-4120-2900
Jun GongDepartment of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.ORCID 0000-0001-8713-1406
Nathalie T NguyenDepartment of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.ORCID 0009-0001-4282-103X
Nicole C LoroñaDepartment of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.ORCID 0000-0002-8302-3157
Domenico CoppolaDepartment of Anatomic Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0001-9090-1205
Clifton G FulmerDepartment of Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic Foundation, Cleveland, Ohio.ORCID 0000-0003-1453-9421
Ozlen SaglamDepartment of Anatomic Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0003-3216-239X
Kun JiangDepartment of Anatomic Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0001-8531-7813
W Douglas CressDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0002-9119-3658
Teresita Muñoz-AntoniaDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0009-0002-2712-8461
Idhaliz FloresDepartment of Basic Sciences, Ponce Research Institute, Ponce Health Sciences University, Ponce, Puerto Rico.ORCID 0000-0003-2130-4508
Edna R GordiánDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0009-0001-6396-5120
José A Oliveras TorresDepartment of Basic Sciences, Ponce Research Institute, Ponce Health Sciences University, Ponce, Puerto Rico.ORCID 0009-0005-4954-3828
Seth I FelderDepartment of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0001-6975-8379
Julian SanchezDepartment of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0002-7198-839X
Jason B FlemingDepartment of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0002-8796-5627
Erin M SiegelDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0003-1779-2510
Jennifer A FreedmanDivision of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.ORCID 0000-0001-6771-4161
Julie DutilDivision of Clinical and Translational Cancer Research, Comprehensive Cancer Center of the University of Puerto Rico, San Juan, Puerto Rico.ORCID 0000-0002-0313-6443
Mariana C SternDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California.ORCID 0000-0001-9777-4683
Brooke L FridleyDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0001-7739-7956
Jane C FigueiredoDepartment of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.ORCID 0000-0001-8040-3341
Stephanie L SchmitGenomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0001-5931-1194
Funding
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CARYN LERMAN · 1985 to 2026
$181.4M
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5M
Using MC1R genotype to impact skin cancer risk behaviors in Hispanics/LatinosU54CA163068 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI Shannon Marie Christy · 2012 to 2026
$23.1M
Using MC1R genotype to impact skin cancer risk behaviors in Hispanics/LatinosU54CA163071 · NCI · PONCE SCHOOL OF MEDICINE · PI Harold I Saavedra · 2012 to 2026
$23.0M
USC PE-GCS: Optimizing Engagement of Hispanic Colorectal Cancer Patients in Cancer Genomic Characterization StudiesU2CCA252971 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JOHN D. CARPTEN, HEINZ JOSEF LENZ · 2021 to 2026
$19.3M
Tissue Modeling CoreU54CA233465 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Bodour Salhia · 2018 to 2026
$11.9M
Translational Research Program in Cancer Differences across PopulationsP50CA285275 · NCI · FRED HUTCHINSON CANCER CENTER · PI AMANDA L KOEHNE · 2024 to 2026
$9.9M
Adding Hispanics to Ongoing GWAS in Colorectal CancerR01CA155101 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI FIGUEIREDO, JANE C. · 2011 to 2015
$4.5M
Variation in tumor-associated immune profiles and colorectal cancer outcomesR01CA248931 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI SCHMIT, STEPHANIE L. · 2021 to 2025
$3.5M
Translational Research Program in Colorectal Cancer DisparitiesP20CA252733 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LI, CHRISTOPHER I · 2020 to 2022
$3.4M
Biological determinants of colorectal cancer outcomes in Latinos of diverseýancestral originsR01CA238087 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI FIGUEIREDO, JANE C., SCHMIT, STEPHANIE L. · 2019 to 2024
$3.2M
Elucidating the role of transcriptomics in driving ethnicity and ancestry-related disparities in colorectal cancerR01CA284732 · NCI · CEDARS-SINAI MEDICAL CENTER · PI Jane C. Figueiredo, Jennifer Ann Freedman · 2024 to 2026
$2.0M
Moffitt Cancer Center (MCC) Team Science AwardNational Cancer Institute (NCI) P20CA252733National Cancer Institute (NCI) P30CA014089National Cancer Institute (NCI) P30CA076292National Cancer Institute (NCI) P50CA285275National Cancer Institute (NCI) R01CA155101National Cancer Institute (NCI) R01CA238087National Cancer Institute (NCI) R01CA248931National Cancer Institute (NCI) R01CA284732National Cancer Institute (NCI) U2CCA252971National Cancer Institute (NCI) U54CA163068National Cancer Institute (NCI) U54CA163071National Cancer Institute (NCI) U54CA233465NCI NIH HHS P20 CA252733NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA076292NCI NIH HHS P50 CA285275NCI NIH HHS R01 CA155101NCI NIH HHS R01 CA238087NCI NIH HHS R01 CA248931NCI NIH HHS R01 CA284732NCI NIH HHS U2C CA252971NCI NIH HHS U54 CA163068NCI NIH HHS U54 CA163071NCI NIH HHS U54 CA233465
6 · The paper itself
Abstract
Admixed populations, including the Hispanic/Latino/a community, are underrepresented in cancer genetic/genomic studies. Leveraging the Latino Colorectal Cancer Consortium (LC3) and other existing datasets, we analyzed whole-exome sequencing data on tumor/normal pairs from 718 individuals with colorectal cancer to map somatic mutational features by ethnicity and genetic similarity. Global proportions of African, Asian, European, and Native American genetic ancestries were estimated using ADMIXTURE. Associations between these proportions and somatic mutational features were examined using logistic regression. APC, TP53, and KRAS were the top three mutated genes across all participants and in the subset of Latino individuals in LC3. In analyses examining recurrently mutated genes, tumors from patients of Latino ethnicity had fewer KRAS and PIK3CA mutations compared with tumors from non-Latino patients. Genetic ancestry overall was associated with CDC27 mutation status, and African genetic ancestry was associated with SMAD2 mutation status. In exome-wide analyses, African genetic ancestry was significantly associated with higher odds of mutation in KNCN and TMEM184B. Native American genetic ancestry was associated with a lower frequency of microsatellite instability-high tumors. The SBS11 mutational signature was associated with Native American genetic ancestry as well as Latino ethnicity. In an independent replication dataset, MSK-IMPACT, estimates of association were largely consistent in direction but nonsignificant. A meta-analysis of LC3 and MSK-IMPACT showed that African genetic ancestry was significantly associated with KRAS mutation status and MSI status. This work facilitates precision medicine initiatives by providing insights into the contribution of genetic ancestry to molecular features of colorectal tumors. Significance: Analysis of tumors from various populations can broadly characterize genomic landscapes and enhance precision medicine strategies.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Colorectal Tumors in Diverse Patient Populations Feature a Spectrum of Somatic Mutational Profiles. · full record | OpenQuestion